Table 2 Treatments used during follow-up according to the presence (MSGB+) or absence (MSGB–) of granuloma on minor salivary gland biopsy (MSGB)
Total N = 26 | MSGB+ N = 12 | MSGB– N = 14 | P | |
|---|---|---|---|---|
Systemic corticosteroids | ||||
Total, n (%) | 23 (88%) | 10 (83%) | 13 (93%) | 0.58 |
Intravenous bolus, n (%) | 5/23 (22%) | 2/10 (20%) | 3/13 (23%) | 1 |
Delay of initiation after diagnosis, days, median (min–max) | 17 (1–91) | 18 (4–51) | 15 (1–91) | 0.57 |
Duration of treatment, months, median (min–max) | 8 (1–20) | 13 (3–20) | 7 (1–16) | 0.04 |
Children with inactive uveitis at last follow-up with corticosteroids alone, n (%) | 3/23 (13%) | 0 | 3/13 (23%) | 0.22 |
Methotrexate | ||||
Total, n (%) | 22 (85%) | 12 (100%) | 10 (71%) | 0.10 |
Delay of initiation after diagnosis, months, median (min–max) | 5 (0.5–35) | 7 (0.5–35) | 4 (2.5–12) | 0.57 |
Initiated without anti-TNF, n (%) | 11/22 (50%) | 6/12 (50%) | 5/10 (50%) | 1 |
Initiated with anti-TNF, n (%) | 11/22 (50%) | 6/12 (50%) | 5/10 (50%) | 1 |
Children with inactive uveitis at last follow-up with methotrexate alone (without anti-TNF), n (%) | 7/11 (64%) | 4/6 (67%) | 3/5 (60%) | 1 |
Anti-TNF | ||||
Total, n (%) | 16 (62%) | 8 (67%) | 8 (57%) | 0.70 |
Delay of initiation after diagnosis, months, median (min–max) | 7 (0.5–35) | 8 (0.5–35) | 7 (2–33) | 0.78 |
Associated with methotrexate, n (%) | 15/16 (94%) | 8/8 (100%) | 7/8 (88%) | 1 |
Children with inactive uveitis at last follow-up with anti-TNF, n (%) | 16/16 (100%) | 8/8 (100%) | 8/8 (100%) | 1 |
Uveitis in remission at last follow-up, n (%) | 6 (23%) | 2 (17%) | 4 (29%) | 0.65 |
Follow-up time after uveitis onset, years, median (min–max) | 3.1 (0.6–6.3) | 3.2 (0.6–6.3) | 3.1 (1.3–5.6) | 0.83 |